HTML Microdata document

This HTML5 document contains 72 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

Prefix	IRI
n2	http://linked.opendata.cz/resource/drugbank/drug/
dcterms	http://purl.org/dc/terms/
n8	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/chebi/
n18	http://linked.opendata.cz/resource/AHFS/
n10	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/wikipedia/
n19	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/pharmgkb/
n6	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/bindingdb/
n20	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/pubchem-compound/
n15	http://bio2rdf.org/drugbank:
n16	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/pubchem-substance/
adms	http://www.w3.org/ns/adms#
n7	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/drugbank/
n12	http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdf	http://www.w3.org/1999/02/22-rdf-syntax-ns#
n14	http://linked.opendata.cz/resource/drugbank/medicinal-product/
owl	http://www.w3.org/2002/07/owl#
n3	http://linked.opendata.cz/ontology/drugbank/
n4	http://linked.opendata.cz/resource/drugbank/property/
xsdh	http://www.w3.org/2001/XMLSchema#
n9	http://linked.opendata.cz/resource/drugbank/drug/DB00720/identifier/chemspider/
n17	http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item: n2:DB00720
rdf:type: n3:Drug
n3:description: A diphosphonate which affects calcium metabolism. It inhibits bone resorption and soft tissue calcification. [PubChem]
n3:group: approved investigational
n3:halfLife: Approximately 13 hours.
n3:indication: For the management of hypercalcemia of malignancy and as an adjunct in the management of osteolysis resulting from bone metastases of malignant tumors.
owl:sameAs: n12:DB00720 n15:DB00720
dcterms:title: Clodronate
adms:identifier: n6:50216172 n7:DB00720 n8:110423 n9:23731 n10:Clodronate n16:46508646 n19:PA10239 n20:25419
n3:mechanismOfAction: The bisphosphonate group binds strongly to the bone mineral, hydroxyapatite. This explains the specific pharmacological action of these compounds on mineralized tissues, especially bone. The exact mechanism of action of clodronate is not known, however it is known that it does not inhibit protein isoprenylation but can be metabolized intracellularly to a β-γ-methylene (AppCp-type) analog of ATP (AppCCl2p), which is cytotoxic to macrophages in vitro. Inhibition of the ADP/ATP translocase by the metabolite AppCCl2p is a likely route by which clodronate causes osteoclast apoptosis and inhibits bone resorption. Recently, the slime mold <i>Dictyostelium discoideum</i> was shown to take up bisphosphonates by pinocytosis. In these cells, clodronate, but not other pharmacologically active bisphosphonates, was incorporated into adenine nucleotides, which could potentially explain why this bisphosphonate sometimes seems to act differently than the other bisphosphonates. Clodronate, like all biphosphonates, also binds protein-tyrosine-phosphatase.
n3:synonym: Clodronate Acidum Clodronicum Acide Clodronique Acido Clodronico Dichloromethylene-1,1-diphosphonic acid Clodronsaeure (Dichloro-phosphono-methyl)-phosphonic acid Dichloromethanediphosphonic acid (Dichloromethylene)bisphosphonic acid Dichloromethylidene diphosphonate (Dichloromethylene)diphosphonic acid Dichloromethylene-1,1-bisphosphonic acid Clodronsäure
n3:toxicity: Decreases in serum calcium following substantial overdosage may be expected in some patients. Signs and symptoms of hypocalcemia also may occur in some of these patients.
n17:hasAHFSCode: n18:92-00-00
n3:foodInteraction: Food decreases absorption. Take on an empty stomach.
n3:proteinBinding: 2%-36%
n3:salt
n3:synthesisReference: Fritz Demmer, Berthold Stemmle, "Clodronate-containing medicaments and a process for the preparation thereof." U.S. Patent US4859472, issued September, 1980.
n3:IUPAC-Name: n4:271B4D99-363D-11E5-9242-09173F13E4C5
n3:InChI: n4:271B4D9F-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula: n4:271B4D9E-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight: n4:271B4D9B-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight: n4:271B4D9C-363D-11E5-9242-09173F13E4C5
n3:SMILES: n4:271B4D9D-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility: n4:271B4DAE-363D-11E5-9242-09173F13E4C5 n4:271B4D97-363D-11E5-9242-09173F13E4C5
n3:logP: n4:271B4DB0-363D-11E5-9242-09173F13E4C5 n4:271B4D95-363D-11E5-9242-09173F13E4C5 n4:271B4D98-363D-11E5-9242-09173F13E4C5
n3:logS: n4:271B4D96-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count: n4:271B4DA5-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count: n4:271B4DA6-363D-11E5-9242-09173F13E4C5
n3:InChIKey: n4:271B4DA0-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-: n4:271B4DA1-363D-11E5-9242-09173F13E4C5
n3:Polarizability: n4:271B4DA3-363D-11E5-9242-09173F13E4C5
n3:Refractivity: n4:271B4DA2-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count: n4:271B4DA4-363D-11E5-9242-09173F13E4C5
n3:absorption: After oral administration, absorption is estimated at 1–3% of the ingested dose because of the low uptake from the gastrointestinal tract.
n3:affectedOrganism: Humans and other mammals
n3:casRegistryNumber: 10596-23-3
n3:category
n3:containedIn: n14:271B4D92-363D-11E5-9242-09173F13E4C5 n14:271B4D94-363D-11E5-9242-09173F13E4C5 n14:271B4D93-363D-11E5-9242-09173F13E4C5
n3:Bioavailability: n4:271B4DAA-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter: n4:271B4DAC-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule: n4:271B4DAD-363D-11E5-9242-09173F13E4C5
n3:Melting-Point: n4:271B4DAF-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings: n4:271B4DA9-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge: n4:271B4DA8-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five: n4:271B4DAB-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name: n4:271B4D9A-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-: n4:271B4DA7-363D-11E5-9242-09173F13E4C5